Cav1.2 (encoded by CACNA1C) is the pore-forming α1 subunit of L-type voltage-gated calcium channels (LTCCs) widely expressed in the brain, heart, and smooth muscle. In neurons, Cav1.2 channels mediate long-lasting calcium influx in response to membrane depolarization, playing critical roles in synaptic plasticity, gene transcription, and neuronal survival.[1][2]
In neurodegenerative diseases, altered Cav1.2 expression and function contribute to calcium dyshomeostasis, excitotoxicity, and neurodegeneration. Cav1.2 channels are therapeutic targets for Alzheimer's disease and Parkinson's disease, with calcium channel blockers showing neuroprotective effects in preclinical models.[3]
Cav1.2 is the α1C subunit, which forms the ion-conducting pore. The functional channel is a complex of:
The α1 subunit contains four homologous domains (I-IV), each with six transmembrane segments (S1-S6):
| Domain | Location | Function |
|---|---|---|
| N-terminus | Cytoplasmic | Modulation, G-protein interaction |
| I-II linker | Cytoplasmic | β subunit binding, inactivation |
| III-IV linker | Cytoplasmic | Inactivation gate |
| C-terminus | Cytoplasmic | CaM binding, transcription regulation[4] |
Cav1.2 is regulated by calmodulin binding to the C-terminal IQ motif. Rising intracellular calcium causes Ca²⁺-CaM to bind and induce channel inactivation, preventing excessive calcium entry. This negative feedback is critical for calcium homeostasis.[5]
Cav1.2 channels exhibit:
In Alzheimer's disease, Cav1.2 dysfunction contributes to pathology:
Studies show that Cav1.2 levels are elevated in AD hippocampus, and LTCC blockers improve memory in AD mouse models.
Clinical trials (STEADY-PD) tested isradipine in early PD, though results were inconclusive.
During cerebral ischemia:
| Drug | Class | Clinical Use |
|---|---|---|
| Nifedipine | Dihydropyridine | Hypertension, angina |
| Verapamil | Phenylalkylamine | Arrhythmia, migraine |
| Diltiazem | Benzothiazepine | Hypertension, angina |
| Isradipine | Dihydropyridine | PD investigation |
Striessnig et al. L-type Ca2+ channel Cav1.2 (2014). 2014. ↩︎
Bocian et al. Cav1.2 in neuronal function and disease (2013). 2013. ↩︎
Hofmann et al. Calcium channelopathies (2019). 2019. ↩︎
Tang L, et al. Structure of the CaV1.2 channel in complex with antihypertensive drugs. Nature. 2019. ↩︎
Ben-Johny M, Yue DT. Calmodulin regulation (calmodulation) of voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2014. ↩︎
Moosmang S, et al. Role of hippocampal Cav1.2 Ca²⁺ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neurosci. 2005. ↩︎
Anekonda TS, Quinn JF. Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. BioDrugs. 2011. ↩︎
Surmeier DJ, et al. What causes the death of dopaminergic neurons in Parkinson's disease?. Prog Neurobiol. 2017. ↩︎
Lee JM, et al. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999. ↩︎
Park J, et al. Calcium channel regulation and autoimmunity in Lambert-Eaton myasthenic syndrome. J Clin Invest. 2010. ↩︎